NewsRoom Articles - Page 72 of 154 - PsychedelicNewsWire (PNW)

WednesdayJan 19, 2022 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Attended This Year’s H.C. Wainwright Bioconnect Virtual Conference

Delic Holdings Corp is a leader in new medicines and treatments for a modern world, with a business network which includes psychedelic wellness clinics, a licensed psilocybin research lab, a famed psychedelic wellness event, and dedicated media platforms The company announced that its co-founder and CEO, Matt Stang, presented at the H.C. Wainwright Bioconnect Virtual Conference on January 10-13, 2022 Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, has long been known for its role as a trailblazer in improving access to health benefits across the country and reframing the conversation…

WednesdayJan 19, 2022 9:00 am

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) CEO Shares Company Success Insights on Bell2Bell Podcast

Mr. Josh Bartch, the CEO, Chairman, and Co-Founder of Mydecine, attributed the company’s success to its phased approach to product research and development He noted significant strides in smoking cessation and PTSD research over the 2021 calendar year, which will be integral to operations in the new year Mr. Bartch was also proud of the current efficacy data around psilocybin to treat nicotine dependance which is significantly better than what is available in the market Going into 2022, Mydecine will embark on more clinical studies on smoking cessation and PTSD, focus more on novel compound production and growing its Mindleap…

WednesdayJan 19, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Emerging as Psychedelics Leader, Looking Forward to ‘Transformative’ Year

Company marked host of major milestones and accomplishments in 2021 Approvals, licenses, expansions and growth all essential pieces of Cybin success CYBN’s innovative operational and R&D pipeline platforms expected to support four first-in-human clinical studies in 2022 As the new year begins, Cybin (NEO: CYBN) (NYSE American: CYBN) couldn’t be in a better position. The biopharmaceutical company’s commitment to establishing a stronghold in the psychedelics space paid off big last year, with the company marking a host of major milestones and accomplishments and looking toward more of the same for 2022. "2021 was an exciting year for Cybin,” said Cybin CEO…

TuesdayJan 18, 2022 3:45 pm

Washington State Bill Seeks to Legalize Medical Use of Psilocybin

Last week, two legislators from Washington State introduced a proposal that would legalize psilocybin services in the state. The bill, dubbed SB5660, would permit individuals aged 21 and above to consume products that contain psilocin and psilocybin under the supervision of a state-licensed and trained psilocybin service administrator. Psilocin and psilocybin are the two primary active ingredients found in magic mushrooms. Individuals with certain medical conditions that render them unable to go to a licensed service center would be allowed to meet with facilitators remotely and be administered these products at home. Other individuals who don’t meet this criterion would…

FridayJan 14, 2022 11:06 am

Health Canada Permits Physicians to Prescribe Psychedelic Drugs for Mental Illnesses

The Special Access Program by Health Canada allows patients with life-threatening mental health conditions whose previous treatments have been ineffective to begin using MDMA and psilocybin mushrooms as part of their treatment. Before physicians were allowed to prescribe these medicines, the drugs could only be used after an exemption was granted for individual palliative cases by Health Canada. David Harder states that this move, which allows physicians to prescribe psychedelics in their practices, is a huge shift with regard to psychedelic legalization in Canada. Harder, who operates the ATMA Calgary Urban Journey Center, added that physicians would still be required…

ThursdayJan 13, 2022 1:56 pm

Veterans with PTSD to Receive Service Dogs Under PAWS Act

Service dogs in the United States are usually given to former service members of the military as a form of support after the soldiers have served the country. Individuals who qualify to receive the free service dogs have to meet various qualifications, which include having emotional or physical disabilities. K9s for Warriors, advocates and Canine Companions have been calling for the Veterans Affairs Department to provide support to veterans with PTSD by giving them service dogs. However, until recently, individuals with mental trauma weren’t eligible to receive these support dogs. Canine Companions offers service dogs to children, adults and veterans…

WednesdayJan 12, 2022 12:37 pm

Four Hidden Psychedelic Truths in ‘The Matrix Resurrections’

“The Matrix” was first released in 1999, and since then, three more sequels have been released: “The Matrix Reloaded,” “The Matrix Revolutions” and “The Matrix Resurrections,” each one more thrilling and captivating than the last. One thing that may catch your eye with this latest release is how trippy the film is, from guided spiritual journeys to flashbacks that bend reality. Today, we look at ways in which “The Matrix Resurrections” is more psychedelic than the first film in the sequence. Slowing time In the first movie, Neo got out of trouble by slowing down the time around him. In…

WednesdayJan 12, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance CYB004

Cybin awarded notice for company’s innovative treatment of anxiety disorders Approval demonstrates company’s dedication to discovery and development of psychedelic-based compounds for addressing mental health Anxiety disorders rank among the most common mental illnesses in the country Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its strategic plan to strengthen its position as leading innovator in developing putative psychedelic compounds. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for its patent application for an innovative treatment of anxiety disorders (https://ibn.fm/8hMWh). Cybin announced that it has been awarded a USPTO…

TuesdayJan 11, 2022 1:03 pm

Psychedelics May Shed Light on How Perception Occurs

Anil Seth, a neuroscientist at the University of Sussex, has been studying how the brain helps individuals perceive the world around them. The researcher is interested in what psychedelics like LSD can reveal to us about how the brain develops different perceptions. Seth has tried LSD and ayahuasca, both experiences leaving him with a strengthened conviction that these substances possess the potential to teach us about the workings of the brain, which produces perceptions. He isn’t the only advocate, as more neuroscientists, armed with computational models of the brain, EEG recordings, fMRI scans and volunteer reports, try to understand how…

MondayJan 10, 2022 1:36 pm

University of Texas-Austin Launches Center for Psychedelic Research and Therapy

The University of Texas at Austin recently established a Center for Psychedelic Research and Therapy. This comes months after the state’s governor signed a proposal that instructs the state to conduct research on the benefits and risks of ketamine, MDMA and psilocybin for veterans. Prof. Charles B. Nemeroff, the center’s co-lead, stated that the center would bring more scientific expertise and rigor to study psychedelic therapy. Nemeroff is also the chair of the Department of Behavioral Sciences and Psychiatry at the Dell Medical School. The center, which is the first of its kind in the state, will allow researchers to…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000